| |
 |
|
|
Inventor: Watts; Eric A.
Address: Harlow, GB2
No. of patents: 11
Patents:
| Patent Number |
Title Of Patent |
Date Issued |
| 4866039 |
Peptides containing the 18 to 23 residues of vasoactive intestinal peptide, and analogues |
September 12, 1989 |
| Peptides comprising, in sequence, units selected from the amino acid residues 17 to 24 of VIP, and consisting at least of the amino acid residues 18 to 23, or an analogue thereof wherein one or more of the amino acid residues is replaced by an equivalent other amino acid; having anti |
| 4853394 |
N-('-B-hydroxyethylpiperid-4-yl esters and amides |
August 1, 1989 |
| Compounds of formula (I) and pharmaceutically acceptable salts thereof:wherein: Ar is a group of formula (a): ##STR1## wherein either R.sub.2 is C.sub.1-6 alkoxy and one of R.sub.3, R.sub.4 and R.sub.5 is hydrogen and the other two are selected from hydrogen, halogen, CF.sub.3, CX.su |
| 4816453 |
N-heterocyclic derivatives of benzamides and their use in treating gastric and intestinal disord |
March 28, 1989 |
| Compounds of formula (i) and pharmaceutically acceptable salts thereof: ##STR1## wherein: m and n are independently 1 or 2 and p is 0, 1 or 2 such that m+n+p.gtoreq.3;R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1-6 alkyl, phenyl or phenyl-C.sub.1-6 alkyl, which phenyl moiet |
| 4737487 |
VIP type peptides |
April 12, 1988 |
| Peptides comprising, in sequence, units selected from the amino acid residues 11 to 23 of vasoactive intestinal peptide (VIP) and consisting at least of the amino acid residues 15 to 20, or an analogue thereof wherein one or more of the amino acid residues is replaced by an equivalent ot |
| 4569940 |
Certain 5-N-mono- or disubstituted sulfamoyl benzamides having use in treatment of emesis, impai |
February 11, 1986 |
| Compounds of formula (I): ##STR1## wherein: one of X and Y is CO and the other is NH;R.sub.1 is C.sub.1-6 alkoxy or C.sub.1-6 alkylthio;R.sub.2 is hydrogen, trifluoromethyl, C.sub.1-6 alkylthio, C.sub.1-7 acyl, C.sub.1-7 acylamino, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkylsulphinyl, |
| 4533498 |
Compounds |
August 6, 1985 |
| Compounds of formula (I), pharmaceutically acceptable salts, quaternary derivatives and N-oxides thereof, and pharmaceutically acceptable solvates of any of the foregoing: ##STR1## wherein p is 1 to 3;B is C.sub.1-7 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkyl-C.sub.1-2 alky |
| 4499099 |
Nortropane and granatane type compounds useful in treating psychosis |
February 12, 1985 |
| Pharmaceutical compositions comprising compounds of formula (I) or pharmaceutically acceptable salts and/or N-oxides and/or solvates thereof: ##STR1## wherein: R.sub.1 is a C.sub.1-6 alkoxy or C.sub.1-6 alkylthio group; andone of R.sub.2, R.sub.3 and R.sub.4 is hydrogen, the second is C. |
| 4459300 |
Pharmaceutically active aza-bicyclo benzamide derivatives |
July 10, 1984 |
| Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein: n, p and q independently are 0 to 2;R.sub.5 is hydrogen or C.sub.1-6 alkyl;R.sub.6 is C.sub.1-7 alkyl or a group --(CH.sub.2).sub.s R.sub.7 where s is 0 to 2 and R.sub.7 is a C.sub.3-8 cycloalkyl gr |
| 4410535 |
Aza-bicyclo-benzamide derivatives and pharmaceutical compositions and use thereof |
October 18, 1983 |
| Compounds of the formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein: R.sub.1 is C.sub.1-6 alkyl;R.sub.2 is hydrogen or C.sub.1-7 acyl;R.sub.3 is C.sub.1-6 alkyl;R.sub.4 is a group CH.sub.2 R.sub.5 wherein R.sub.5 is hydrogen, C.sub.3-8 cycloalkyl or phenyl option |
| 4267175 |
Benzamide derivatives |
May 12, 1981 |
| A compound of the formula (I), and pharmaceutically acceptable salts thereof: ##STR1## wherein: R.sub.1 is a C.sub.1-6 alkoxy group;R.sub.2 and R.sub.3 are the same or different and are hydrogen, halogen, CF.sub.3, hydroxy, C.sub.1-6 alkoxy, C.sub.2-7 acyl, amino, amino substitut |
| 4213983 |
Treating gastro-intestinal disorders and emesis with n-(heterocyclic substituted) benzamides |
July 22, 1980 |
| Compounds of the formula (I), and their pharmaceutically acceptable salts: ##STR1## wherein: R.sub.1 is a C.sub.1-6 alkoxy group;R.sub.2 and R.sub.3 are the same or different and are hydrogen, halogen, CF.sub.3, hydroxy, C.sub.1-6 alkoxy, C.sub.2-7 acyl, amino, amino substituted by o |
|
|
|
